Advertisement
Journal Home
Search for

Volume 201, Issue 6, Pages 547-552 (December 2009)


View previous. 3 of 40 View next.

Editor's ChoiceEditor's CommentarySafety of influenza vaccination during pregnancy

Pranita D. Tamma, MDaCorresponding Author Informationemail address, Kevin A. Ault, MDcd, Carlos del Rio, MDdef, Mark C. Steinhoff, MDg, Neal A. Halsey, MDab, Saad B. Omer, MBBS, MPH, PhDde

Received 4 September 2009; received in revised form 25 September 2009; accepted 29 September 2009. published online 22 October 2009.

The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommends routine influenza vaccination for all women who are or will be pregnant during the influenza season. During seasonal influenza epidemics, during previous pandemics, and with the current influenza A (H1N1) pandemic, pregnancy places otherwise healthy women at increased risk for serious complications from influenza, including death. Inactivated influenza vaccine can be safely and effectively administered during any trimester of pregnancy. No study to date has demonstrated an increased risk of either maternal complications or adverse fetal outcomes associated with inactivated influenza vaccination. Moreover, no scientific evidence exists that thimerosal-containing vaccines are a cause of adverse events among children born to women who received influenza vaccine during pregnancy. In this article, we review the evidentiary basis for the recommendation of vaccination of all women who will be pregnant during the influenza season and safety data of influenza vaccination during pregnancy.

a Division of Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD

b Institute for Vaccine Safety, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

c Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA

d Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA

e Hubert Department of Global Health, Rollins School of Public Health, Emory University School of Medicine, Atlanta, GA

f Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA

g Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Corresponding Author InformationReprints: Pranita D. Tamma, MD, Department of Pediatrics Infectious Diseases, Johns Hopkins University School of Medicine, 200 N. Wolfe St., Room 3095, Baltimore, MD 21287

 Dr Tamma is supported by a National Institutes of Health (NIH) fellowship training Grant. Dr del Rio is supported by Grants from NIH (HIV vaccine trials network and vaccine treatment and evaluation units), Centers for Disease Control and Prevention (CDC), Emory Global Health Institute, Merck and Co., Inc. (West Point, PA), and Sanofi Pasteur. Dr Steinhoff is supported by the Bill and Melinda Gates Foundation, NIH, and Wyeth Vaccines. Dr Halsey is supported by Berna, Intercel, Merck (North Wales, PA), Novartis, CDC, and NIH. Dr Omer is supported by the Bill and Melinda Gates Foundation, CDC, Merck (North Wales, PA), and Emory Global Health Institute.

 Dr Omer was awarded the Maurice R. Hilleman Early-stage Career Investigator Award by the National Foundation for Infectious Diseases, funded by an unrestricted educational Grant to the National Foundation for Infectious Diseases from Merck and Co., Inc. However, Dr Omer had no direct interaction with Merck and Co., Inc. related to this award.

PII: S0002-9378(09)01108-9

doi:10.1016/j.ajog.2009.09.034


View previous. 3 of 40 View next.

Advertisement